Fourth-quarter net product sales from prescriptions increased by 46% to $361,000 versus Q3 Easing of COVID-19 restrictions helped fuel higher sales, increased face-to-face meetings with healthcare professionals SOLANA BEACH, Calif. , March 08, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.
SOLANA BEACH, Calif. , March 01, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company is scheduled to release its fourth quarter and full year 2021 financial results
Revisiting the risk of tardive dyskinesia with metoclopramide use in diabetic gastroparesis: results of a real-world data driven epidemiology study SOLANA BEACH , Calif., and CHICAGO , Feb. 24, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused
New Research Study Demonstrates Increased Acceptance Among Healthcare Providers Patient Testimonial Videos Detail Benefits Included and Available on GimotiRx.com Expanded Coverage with recent New York Medicaid Approval SOLANA BEACH, Calif. , Feb. 17, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma ,
SOLANA BEACH, Calif. and CHICAGO , Feb. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI) diseases, and EVERSANA Life Science Services, LLC , an independent provider of global commercial
SOLANA BEACH, Calif. , Jan. 04, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (G.I.) diseases, today announced that the Company will participate in the H.C.
SOLANA BEACH, Calif. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the quarter ended September 30, 2021 and recent corporate
SOLANA BEACH, Calif. , Nov. 03, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that the Company is scheduled to release its third quarter 2021 financial results on
Health care practitioners’ perception of nasal route of administration similar to IV; 92% intend to prescribe GIMOTI Evoke attending American College of Gastroenterology (ACG) Annual Conference in Las Vegas , October 22-27, 2021 SOLANA BEACH, Calif. and CHICAGO , Oct.
Award for “Spray Away” Campaign seeking to drive patient and provider awareness for the novel nasal spray treatment of symptoms of Diabetic Gastroparesis SOLANA BEACH, Calif. , Sept. 29, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma® (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments
